This inventor holds 24 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in HIV Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited, Viiv Healthcare UK (No. 4) Limited. Active years: 2010-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Wallingford, CT (US) (2018 - 2021)
- Southington, CT (US) (2010 - 2022)
- Doylestown, PA (US) (2022)
Company Filing History:
14 out of 3,742 
6 out of 45 
4 out of 8 Years Active: 2010-2025
Areas of Expertise:
Title: Jacob Swidorski: Innovator in Antiviral Compounds
Introduction
Jacob Swidorski, based in Southington, CT, is an accomplished inventor known for his significant contributions to the field of antiviral medications. With a remarkable portfolio of 23 patents, he has made strides in developing compounds aimed at treating complex viral infections, including HIV.
Latest Patents
One of Swidorski's latest innovations encompasses the development of triterpenoids with HIV maturation inhibitory activity. This patent outlines compounds that not only exhibit unique antiviral properties but also include pharmaceutical compositions and methods for their use. Specifically, the compounds involve triterpenoids represented by Formula I, with various cycloalkyl groups and other unique modifications, aiming to aid in the treatment of HIV and AIDS.
Additionally, he has disclosed small molecule inhibitors of galectin-3 (Gal-3), which feature several forms of formula compositions that inhibit this target, further contributing to therapeutic avenues in pharmaceutical sciences.
Career Highlights
Swidorski has had a diverse career, having worked with influential companies such as Bristol Myers Squibb Company and ViiV Healthcare UK (No. 5) Limited. His tenure in these organizations has allowed him to refine his skills in drug development and innovation, contributing to the growing field of antiviral therapies.
Collaborations
Throughout his career, Jacob has collaborated with prominent colleagues, including Alicia Regueiro-Ren and Nicholas A Meanwell. These collaborations have fostered an environment of innovation, enabling the exploration of new ideas and the advancement of cutting-edge therapeutic compounds.
Conclusion
Jacob Swidorski stands out as a leading figure in the realm of antiviral innovations. His extensive patent portfolio and expertise illustrate his commitment to advancing therapeutic options for HIV and related conditions. With ongoing research and collaboration, Swidorski continues to pave the way for future breakthroughs in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile